Northeast Pharmaceutical Group's (SHE:000597) subsidiary, Dongyao Group Shenyang Shide, obtained a drug registration certificate from China's National Medical Products Administration for the levocarnitine oral solution, according to a Shenzhen Stock Exchange disclosure on Thursday.
The drug is used for the treatment of primary systemic carnitine deficiency and for the short-term and long-term treatment of secondary carnitine deficiency caused by congenital metabolic disorders.
The certificate is valid until March 31, 2030, the pharmaceutical company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。